ClinicalTrials.gg
TerminatedNCT03549338Updated Sep 28, 2020Results posted

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

A Phase 2 interventional study of Sym004 and Futuximab in Metastatic Colorectal Cancer, Colorectal Cancer Metastatic and Carcinoma, sponsored by Symphogen A/S. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-28.

Sponsored by Symphogen A/S · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated due to administrative reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,851st of 1,934
2 · median 64
Started
2018
with 95 others
Phase 2
511 of 2,342
66 open now
Registered
1,265th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 1,851st largest by enrollment of the 1,934 interventional ones that give a count, is one of 96 that started in 2018, is one of 511 in phase 2, and was the 1,265th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004 (Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or modotuximab (Arm C), in genomically-selected patients with chemotherapy-refractory metastatic colorectal carcinoma (mCRC) and acquired resistance to anti-epidermal growth factor receptor (anti-EGFR) mAb therapy. The study is designed to evaluate the relative antitumor activity of each agent as assessed by imaging studies performed after 8 weeks of treatment.

Read the detailed description

Following consent and prior to randomization, genomic analysis will be conducted on blood samples obtained from each potential patient. Triple-negative (TN) results as defined in trial eligibility criteria will be required for initial eligibility. Patients with TNmCRC will continue in the screening process. Once deemed fully eligible, patients will be randomized to Arm A, Arm B, or Arm C.

Dosing cycles of 28 days will continue until documented disease progression (PD) or another criterion for discontinuation is met. Antitumor activity will be assessed at the end of every 2 cycles (every 8 weeks [Q8W]). At the End of Cycle 2 (EOC2) tumor assessment:

  • Patients assigned to Arm A (Sym004) with a documented objective response (OR) or stable disease (SD) will continue to receive Sym004; patients at the EOC2 with documented PD will be discontinued from study
  • Patients assigned to Arm B (futuximab) or Arm C (modotuximab) with a documented OR or SD will be crossed-over to receive Sym004; patients with documented PD at the EOC2 (or prior to the EOC2) will be offered the opportunity to crossover to receive Sym004 or will be discontinued from study

To be considered evaluable for antitumor activity assessment, patients must have completed 2 cycles of dosing inclusive of EOC2 disease imaging studies and must have received any amount of their assigned investigational medicinal product (IMP) during that period, or have PD documented by imaging studies prior to the EOC2. Non-evaluable patients and patients discontinuing from study prior to the EOC2 for reasons other than documented PD will not be replaced.

Note: In December 2018, the decision was made to terminate the trial and enrollment was prematurely discontinued. The primary, secondary, and exploratory objectives are no longer applicable. Only clinical safety-related evaluations will be conducted.

03

Conditions studied

  • Metastatic Colorectal Cancer
  • Colorectal Cancer Metastatic
  • Carcinoma

Keywords

  • Metastatic Colorectal Cancer
  • Colorectal Cancer
  • Carcinoma
  • Sym004
  • futuximab
  • modotuximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, ≥ 18 years of age at the time of obtaining .
  • - or cytologically-confirmed mCRC.
  • Microsatellite instability-high (MSI-H) / mismatch repair-deficient (dMMR) tumors must have received prior therapy with pembrolizumab, nivolumab, or other programmed cell death protein-1 ()/programmed death-ligand 1 (PD-L1) pathway blocker, and must have progressed on that therapy.
  • Meeting the protocol definition of TNmCRC assessed in the screening blood test.
  • mCRC currently not amenable to surgical intervention due to either medical or non-resectability of the tumor.
  • according to v1.1, and willingness to undergo a total of 2 of a primary or tumor site(s) considered safely accessible for biopsy.
  • Must have received at least 2 prior regimens of standard chemotherapy for mCRC and must have been to or failed (includes intolerance to) those regimens. Prior standard chemotherapy may not have included TAS-102 or regorafenib, but must have included agents as specified in the protocol.
  • "Acquired" resistance to commercially available anti-EGFR mAbs approved for the treatment of mCRC must have:

    1. Received treatment with an anti-EGFR for ≥16 weeks
    2. Progressive disease (PD) documented by imaging or clinical findings less than or equal to 6 calendar months after cessation of previous anti-EGFR mAb treatment
    3. No more than 6 calendar months from last dose of previous anti-EGFR mAb treatment to date of consent for this trial (regardless of the in which it was used)
  • (ECOG) performance status (PS) of 0 or 1
  • Not of or who agree to use a highly effective method of during the study beginning within 2 weeks prior to the first dose and continuing until 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating or intending to become pregnant before, during, or within 3 months after the last dose of study drug.
  • Prior history of specific mutations (specified in the protocol) in the tumor at the time of any previous assessment.
  • Known, untreated central nervous system (CNS) or , or spinal cord compression; patients with any of these not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
  • An active second or history of another malignancy within the last 5 years, with exceptions.
  • Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.
  • Active uncontrolled bleeding or a known bleeding diathesis
  • Known cardiovascular disease or condition.
  • Non-healing wounds on any part of the body.
  • Significant gastrointestinal abnormality.
  • Skin rash > Grade 1 from prior anti-EGFR therapy at the time of randomization.
  • Unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy

Drugs and Other Treatments Exclusion Criteria:

  • Prior treatment with TAS-102 or regorafenib
  • Any antineoplastic agent for the primary malignancy (standard or ) without delayed toxicity within 4 weeks prior to first administration of IMP and during study with exceptions
  • Any other investigational treatments within 4 weeks prior to and during study; includes participation in any medical device or other therapeutic intervention clinical trials
  • Radiotherapy as specified in the protocol
  • or systemic hormonal therapy (> 10 mg daily prednisone equivalent) within 2 weeks prior to first administration of IMP and during study; allowed therapies are specified in the protocol.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Arm A (Sym004)

    Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8. For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover.

    Drug: Sym004

  • Experimental
    Arm B (Futuximab)

    Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).

    Drug: Futuximab

  • Experimental
    Arm C (Modotuximab)

    Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.

    Drug: Modotuximab

Interventions

  • DrugFutuximabStudies of FutuximabFutuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.

  • Futuximab is one of two mAb components that constitute Sym004.

  • DrugModotuximab

    Modotuximab is one of two mAb components that constitute Sym004.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.

    Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 5) (CTCAE v5). AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology and the severity of the toxicities will be graded according to the CTCAE v5, where applicable.

    Time frame: 4 months

07

Results

Posted Jan 14, 2020
Limitations and caveats
Early termination changed the primary objective to assess the safety of the allocated treatment. Collection of data for secondary and exploratory objectives was omitted. The crossover dose plan as detailed was no longer in effect.

Participant flow

The intended number of patients to be included in this trial was approximately 54 (18 evaluable per Arm). As of the trial termination date, 2 patients were enrolled.

Participant flow — Overall Study
MilestoneArm A (Sym004)Arm B (Futuximab)Arm C (Modotuximab)
Started110
Completed000
Not completed110
Withdrew: Progressive disease100
Withdrew: Clinical progression010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.

Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 5) (CTCAE v5). AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology and the severity of the toxicities will be graded according to the CTCAE v5, where applicable.

Time frame:
4 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.
participantsArm A (Sym004)Arm B (Futuximab)
At least one AE21
At least one SAE10
At least one AE related to Sym00420
At least one AE related to futuximab00
At least one SAE related to Sym00400
At least one SAE related to futuximab00

Adverse events

Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Sym004)0/2 (0%)1/2 (50%)2/2 (100%)
Arm B (Futuximab)0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventArm A (Sym004)Arm B (Futuximab)
Pleural effusionRespiratory, thoracic and mediastinal disorders1/20/1
Most frequent other events
Most frequent other events
EventArm A (Sym004)Arm B (Futuximab)
Dermatitis acneiformSkin and subcutaneous tissue disorders2/21/1
NauseaGastrointestinal disorders2/20/1
FatigueGeneral disorders1/20/1
Abdominal painGastrointestinal disorders1/20/1
InsomniaPsychiatric disorders1/20/1
Infusion-related reactionInjury, poisoning and procedural complications1/20/1
DyspnoeaRespiratory, thoracic and mediastinal disorders1/20/1
CoughRespiratory, thoracic and mediastinal disorders1/20/1
Haemorrhage intracranialNervous system disorders1/20/1

Baseline characteristics

No patients were treated in Arm C due to the early termination of the trial.

Age, Categorical
Age, Categorical(Participants)Arm A (Sym004)Arm B (Futuximab)Arm C (Modotuximab)Total
<=18 years00—0
Between 18 and 65 years11—2
>=65 years00—0
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Sym004)Arm B (Futuximab)Arm C (Modotuximab)Total
Female00—0
Male11—2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Sym004)Arm B (Futuximab)Arm C (Modotuximab)Total
Hispanic or Latino00—0
Not Hispanic or Latino11—2
Unknown or Not Reported00—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Sym004)Arm B (Futuximab)Arm C (Modotuximab)Total
American Indian or Alaska Native00—0
Asian00—0
Native Hawaiian or Other Pacific Islander00—0
Black or African American00—0
White11—2
More than one race00—0
Unknown or Not Reported00—0
Region of Enrollment
Region of Enrollment(participants)Arm A (Sym004)Arm B (Futuximab)Arm C (Modotuximab)Total
United States11—2
08

Study locations

18 sites
  • City of Hope - Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of North Carolina - Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Uniklinik Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
  • Asklepios Kliniken Altona
    Hamburg, 22763, Germany
  • Universitätsmedizin Mannheim
    Mannheim, 68167, Germany
  • Städtisches Klinikum München
    München, 81737, Germany
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
    Napoli, 80131, Italy
  • Università degli Studi della Campania "Luigi Vanvitelli"
    Napoli, 80131, Italy
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Vall d'Hebron Institut d'Oncologia (VHIO)
    Barcelona, 08035, Spain
  • Institut Català d'Oncologia
    Barcelona, 08908, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Hospital Clínico de Valencia
    Valencia, 46010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2019, 3 months.

Results were first posted in Jan 2020, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2018
First posted
Jun 8, 2018
StartActual
Nov 29, 2018
Primary completionActual
Mar 1, 2019
CompletionActual
Mar 9, 2019
Results first posted
Jan 14, 2020
Last update
Sep 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03549338
Lead sponsor
Symphogen A/S
Responsible party
Sponsor
First posted
Jun 8, 2018
Start date
Nov 29, 2018
Primary completion
Mar 1, 2019
Completion
Mar 9, 2019
Results posted
Jan 14, 2020
Last update
Sep 28, 2020

Study contacts

Scott Kopetz, MD,PhD,FACP
principal investigator · The University of Texas MD Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Futuximab

Start the discussion